Lamivudine salicylate is a salt form of the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine, where the active pharmaceutical ingredient (API) is combined with salicylic acid. This formulation is designed to potentially improve the physicochemical properties, such as solubility or stability, of the parent drug lamivudine. The primary and definitive application of lamivudine salicylate is as an antiretroviral agent. Lamivudine itself is a cornerstone in the treatment of human immunodeficiency virus (HIV) infection and chronic hepatitis B virus (HBV) infection. It functions as a chain terminator by inhibiting the viral reverse transcriptase enzyme, thereby preventing viral replication. As a salt of an established API, its development is focused on pharmaceutical use rather than as a general chemical reagent. This compound falls under the category of anti-infective drugs, specifically antiviral agents. Its development and use are strictly within the pharmaceutical realm, aimed at creating effective dosage forms for the management of viral infections.